<PAGE>

                                   FORM 10-QSB

                     U.S. SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20429


(Mark One)
[X]      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
         SECURITIES EXCHANGE ACT OF 1934

                  For the quarterly period ended March 31, 2002

[ ]      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
         THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________________  to ___________________
Commission File Number     0-27227    .
                       ---------------

                          ALLERGY RESEARCH GROUP, INC.
             (Exact name of registrant as specified in its charter)


                 Florida                                 13-3940486

     (State or other jurisdiction of                    (IRS Employer
      incorporation or organization)                 Identification No.)


                 30806 Santana Street, Hayward, California 94544

                    (Address of principal executive offices)

(Issuer's telephone number) (800) 545-9960.
                            --------------


--------------------------------------------------------------------------------
            (Former name, former address and former fiscal year, if
                           changed since last report)

Checkmark whether the issuer (1) has filed all reports required to be filed by
Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days. Yes  X  No
             ---    ---

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date: 15,105,355 shares of Issuer's voting
common stock were outstanding on April 30, 2002.

<PAGE>

                          ALLERGY RESEARCH GROUP, INC.
                            INDEX TO QUARTERLY REPORT
                                 ON FORM 10-QSB

PART I. FINANCIAL INFORMATION                                               PAGE

     ITEM 1. Condensed Consolidated Financial Statements (Unaudited):

             Consolidated Balance Sheets                                      2

             Consolidated Income Statements                                   3

             Consolidated Statements of Cash Flows                            4

             Notes to Condensed Consolidated Financial Statements             5

     ITEM 2. Management's Discussion and Analysis                             6

PART II. OTHER INFORMATION

     ITEM 1. Legal Proceedings                                               10
     ITEM 2. Changes in Securities and Use of Proceeds                       10
     ITEM 3. Defaults Upon Senior Securities                                 10
     ITEM 4. Submission of Matters to a Vote of Security Holders             10
     ITEM 5. Other Information                                               10
     ITEM 6. Exhibits and Reports on Form 8-K                                10

     SIGNATURE                                                               11

                                       1
<PAGE>

ITEM 1. FINANCIAL STATEMENTS

<TABLE>
                          ALLERGY RESEARCH GROUP, INC.
                           CONSOLIDATED BALANCE SHEETS

<CAPTION>
                                                                    March 31,   December 31,
                                                                      2002          2001
ASSETS                                                             -----------  -----------
                                                                   (unaudited)
<S>                                                                <C>          <C>
Current Assets
   Cash and Cash Equivalents                                       $  143,380   $  199,499
   Accounts Receivable, Net of Allowances for Doubtful
      Accounts and Returns, $88,957 and $90,213                       682,505      534,884
   Inventories                                                      1,254,319    1,559,133
   Prepaid Income Taxes                                                12,400       10,800
   Prepaid Expenses and Other Current Assets                          120,713      156,367
   Deferred Tax Assets                                                256,460      220,460
                                                                   -----------  -----------
Total Current Assets                                                2,469,777    2,681,143

Property and Equipment, Net                                           454,095      505,573

Other Assets
   Deposits                                                            21,410       21,410
   Due From Officers                                                  141,577      138,801
   Intangible Assets, Net of Amortization of $14,542 and $13,192       25,911       27,261
                                                                   -----------  -----------
Total Other Assets                                                    188,898      187,472
                                                                   -----------  -----------
Total Assets                                                       $3,112,770   $3,374,188
                                                                   ===========  ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
   Accounts Payable                                                $  660,610   $1,016,027
   Accrued Liabilities                                                133,550      213,611
   Line of Credit  (Note 3)                                           470,064      570,064
   Capital Lease Obligation, Current Portion                           55,214       55,214
   Income Taxes Payable                                                                862
                                                                   -----------  -----------
Total Current Liabilities                                           1,319,438    1,855,778

Long-Term Liabilities
   Capital Lease Obligation, Noncurrent Portion                        30,615       48,647
                                                                   -----------  -----------

Total Liabilities                                                   1,350,053    1,904,425

Stockholders' Equity
   Preferred Stock, $0.25 Par Value, Authorized
      1,000,000 Shares, Issued and Outstanding                           None         None
   Common Stock, $0.001 Par Value, Authorized
      100,000,000 Shares, Issued and Outstanding,
      15,105,355                                                       15,105       15,105
   Additional Paid In Capital                                       1,141,377    1,141,377
   Retained Earnings                                                  606,235      313,281
                                                                   -----------  -----------
Total Stockholders' Equity                                          1,762,717    1,469,763
                                                                   -----------  -----------
Total Liabilities and Stockholders' Equity                         $3,112,770   $3,374,188
                                                                   ===========  ===========
</TABLE>

See Notes to Condensed Consolidated Financial Statements.

                                       2
<PAGE>


                          ALLERGY RESEARCH GROUP, INC.
                         CONSOLIDATED INCOME STATEMENTS
                                   (UNAUDITED)

                                                          Three Months Ended
                                                               March 31,
                                                    ----------------------------
                                                        2002            2001
                                                    -------------  -------------

Revenues                                            $  3,006,187   $  2,858,949
Cost of Sales                                          1,799,210      1,687,687
                                                    -------------  -------------
Gross Profit                                           1,206,977      1,171,262

Operating Expenses
   Selling, General & Administrative                     892,109        946,028
   Research & Development                                 48,709         45,680
                                                    -------------  -------------
Total Operating Expenses                                 940,818        991,708
                                                    -------------  -------------

 Operating Income                                        266,159        179,554

 Other Income (Expense)
   Interest Income                                         2,777          2,795
   Interest Expense                                      (11,981)       (57,892)
                                                    -------------  -------------
 Net Income                                              256,955        124,457

 Provision (Benefit) For Income Taxes                    (36,000)       (53,317)
                                                    -------------  -------------
 Net Income Available to Common Stockholders        $    292,955   $    177,774

 Weighted Average Common Shares Outstanding:          15,105,355     15,055,355

   Basic and Diluted Income Per Common Share        $        .02   $        .01


See Notes to Condensed Consolidated Financial Statements.

                                       3
<PAGE>

<TABLE>
                               ALLERGY RESEARCH GROUP, INC.
                           CONSOLIDATED STATEMENTS OF CASH FLOWS
                                        (UNAUDITED)

<CAPTION>
                                                                           Three Months Ended
                                                                                 March 31,
                                                                            2002          2001
                                                                         ----------   ----------

<S>                                                                      <C>          <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income                                                               $ 292,955    $ 177,774
                                                                         ----------   ----------
   Adjustments to Reconcile Net Income to Net Cash
   Provided By (Used In) Operating Activities
      Depreciation and Amortization                                         55,156       55,740
   Changes in Assets and Liabilities
      (Increase) Decrease in Accounts Receivable                          (147,621)    (228,091)
      (Increase) Decrease in Inventories                                   304,814      232,333
      (Increase) Decrease in Prepaid Expenses and Other Current Assets      34,054      (30,239)
      (Increase) Decrease in Deferred Tax Assets                           (36,000)     (53,317)
      Increase (Decrease) in Accounts Payable & Accrued Liabilities       (435,478)    (147,281)
      Increase (Decrease) in Income Taxes Payable                             (862)           0
                                                                         ----------   ----------
   Total Adjustments                                                      (225,937)    (170,855)
                                                                         ----------   ----------
Net Cash Flows Provided By Operating Activities                             67,018        6,919

Cash Flows From Investing Activities
   Acquisition of Property and Equipment                                    (2,329)      (2,102)
   Repayments From (Advances To) Officers                                   (2,776)       3,583
                                                                         ----------   ----------
Net Cash Flows Provided By (Used In) Investing Activities                   (5,105)       1,481

Cash Flows From Financing Activities
   Proceeds From Line of Credit                                                  0       29,013
   Repayments on Line of Credit                                           (100,000)     (80,290)
   Repayments on Capital Lease Obligations                                 (18,032)      (7,756)
                                                                         ----------   ----------
Net Cash Used In Financing Activities                                     (118,032)     (59,033)
                                                                         ----------   ----------

Decrease in Cash and Cash Equivalents                                      (56,119)     (50,633)

Cash and Cash Equivalents, Beginning of Period                             199,499      188,648
                                                                         ----------   ----------

Cash and Cash Equivalents, End of Period                                 $ 143,380    $ 138,015
                                                                         ==========   ==========
</TABLE>


See Notes to Condensed Consolidated Financial Statements.

                                       4
<PAGE>

                          ALLERGY RESEARCH GROUP, INC.
                 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
                                 MARCH 31, 2002
                                   (UNAUDITED)

Note 1 - The accompanying unaudited Consolidated Financial Statements of
         Allergy Research Group, Inc. ("the Company") have been prepared in
         accordance with generally accepted accounting principles for interim
         financial information and the instructions to Form 10-QSB. Accordingly,
         they do not include all the information and footnotes required by
         generally accepted accounting principles for complete financial
         statements. In the opinion of management, all adjustments (which
         include only normal recurring adjustments) necessary to present fairly
         the financial position, results of operations and cash flows for all
         periods presented have been made. The results of operations for the
         three-month period ended March 31, 2002 are not necessarily indicative
         of the operating results that may be expected for the entire year
         ending December 31, 2002. These financial statements should be read in
         conjunction with the Company's financial statements and accompanying
         notes thereto as of and for the year ended December 31, 2001, filed
         with the Company's Annual Report on Form 10-KSB on April 1, 2002.

         Certain accounts from prior years have been reclassified to conform to
         the current year's presentation. These changes had no effect on
         previously reported results of operations or total stockholders'
         equity.

Note 2 - Basic earnings or loss per share is based on the weighted average
         number of common shares outstanding. Diluted earnings or loss per share
         is based on the weighted average number of common shares outstanding
         and dilutive common stock equivalents. All earnings per share amounts
         in these financial statements are basic earnings per share as defined
         by SFAS No. 128, "Earnings Per Share." Diluted weighted average shares
         outstanding exclude the potential common shares from options because to
         do so would be antidilutive.

         The computation of basic income (loss) per share is as follows:


                                                    Three Months   Three Months
                                                       Ended          Ended
                                                      3/31/02        3/31/01
         Numerator-Net Income Available
         to Common Stockholders                     $  292,955     $  177,774
                                                    ===========    ===========

         Denominator-Weighted Average Number
         of Common Shares Outstanding               15,105,355     15,055,355
                                                    ===========    ===========

         Basic and Diluted Income Per Common
         Share                                      $     0.02     $     0.01
                                                    ===========    ===========




Note 3 - On May 17, 2001, the Company entered into an agreement with City
         National Bank to replace the former line of credit with Aerofund
         Financial, Inc. and to provide additional funding if needed. The
         replacement line of credit of up to $1,200,000 is for twelve months,
         bearing interest at prime plus two percent computed on a monthly basis.
         The City National Bank prime rate at March 31, 2002 was 4.75%. Interest
         is due monthly. The agreement matures on June 5, 2002, at which time it
         will be renegotiated or paid in full. The note is secured by
         substantially all of the assets of the Company and is personally
         guaranteed by the officers of the Company.

                                       5
<PAGE>

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

GENERAL

         The following discussion should be read in conjunction with the
Company's financial statements and the notes thereto and the other financial
information appearing elsewhere in this document. In addition to historical
information, the following discussion and other parts of this document contain
certain forward-looking information. When used in this discussion, the words
"believes," "anticipates," "expects," and similar expressions are intended to
identify forward-looking statements. Such statements are subject to certain
risks and uncertainties, which could cause actual results to differ materially
from those projected due to a number of factors beyond the Company's control.
The Company does not undertake to publicly update or revise any of its
forward-looking statements even if experience or future changes show that the
indicated results or events will not be realized. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak only as of
the date hereof. Readers are also urged to carefully review and consider the
Company's discussions regarding the various factors, which affect its business,
included in this section and elsewhere in this report.

RESULTS OF OPERATIONS

         Please refer to the financial statements, which are a part of this
report, for further information regarding the results of operations of the
Company.

         PERIOD ENDED MARCH 31, 2002 COMPARED TO MARCH 31, 2001

         The Company's net sales were $3,006,187 for the first quarter ended
March 31, 2002, compared with $2,858,949 for the same period in 2001. The
increase of $147,238 or 5% is primarily attributable to the Company's decrease
in sales in December 2001 as compared to the prior twelve months, which was
offset by an increase in sales during January 2002 due to some of our larger
accounts not ordering until after year-end. Generally speaking, the Company's
sales typically average approximately $1,000,000 a month.

         Cost of sales increased $111,523 to $1,799,210 for the three months
ended March 31, 2002, compared to $1,687,687 for the three months ended March
31, 2001. Cost of materials increased because the volume of capsules in each
container of selected products was increased without passing the cost on to the
consumer. The volume change was made in an effort to increase the value of the
product in anticipation of generating increased sales. The cost of freight has
also increased. Gross profit margins decreased approximately .9% for the first
quarter, approximating 40% for 2002.

         During the quarter ended March 31, 2002, the Company recorded net
income of $292,955 compared to net income of $177,774 for the same period in
2001. The increase of $115,181 is due primarily to a decrease in selling,
general and administrative expenses such as conventions, legal and professional
fees, and interest expense for the first quarter 2002 compared to the same
quarter last year. The Company renegotiated the line of credit, which
significantly reduced interest expense beginning in June 2001, reflecting a
decrease of approximately $45,900 for first quarter 2002 compared to the same
period last year. Interest expense decreased because the Company has reduced the
outstanding line of credit balance from $929,200 at March 31, 2001 to $470,064
at March 31, 2002, and as a result of the above market interest rate the Company
was paying for that line of credit prior to renegotiating the loan. The line of
credit is used to finance accounts receivable and inventory.

         As of March 31, 2002, the Company recorded a deferred tax asset of
$256,460 to be realized as a result of future taxable income offset by net
operating loss carryforwards. As of fiscal year ended December 31, 2001, the
Company had approximately $3,000,000 and $1,350,000, respectively, available in
federal and state net operating loss carryforwards to offset future taxable
income, which expire principally in the year 2020.

                                       6
<PAGE>

LIQUIDITY AND CAPITAL RESOURCES

         THREE MONTHS ENDED MARCH 31, 2002 COMPARED TO MARCH 31, 2001

         At March 31, 2002, the Company had positive working capital of
$1,150,339, compared to a working capital at March 31, 2001 of $542,519. The
Company has been successful in paying down its outstanding debt as a result of
overall decreased operating expenses, and as evidenced by a decrease in
outstanding accounts payable to $660,610 at March 31, 2002 from $787,493 at
March 31, 2001. The Company continues to finance its inventory and accounts
receivable under a line of credit and through its income from operations. The
line of credit outstanding at March 31, 2002 was $470,064 compared to $929,200
at March 31, 2001.

         Net cash flow provided by operating activities was $67,018 for the
three months ended March 31, 2002. This was primarily the result of net income
of $292,955, increased by depreciation expense of $55,156 and a decrease in
inventory of $304,814. These figures were offset by an increase in accounts
receivable of $147,621 and a decrease of accounts payable and accrued
liabilities of $435,478. Net cash flow provided by operating activities for the
three months ended March 31, 2001 was $6,919, due to net income of $177,774,
increased by depreciation of $55,740, a decrease in inventory of $232,333. This
was offset by an increase in accounts receivable of $228,091 and a decrease in
accounts payable and accrued liabilities of $147,281.

         Net cash flow provided by (used in) investing activities was ($5,105)
and $1,481 for the three months ended March 31, 2002 and March 31, 2001,
respectively, which was used primarily for the acquisition of property and
equipment, offset in 2002 by advances to officers of $2,776 and in 2001 by
repayments from officers of $3,583.

         Net cash flow used in financing activities was $118,032 for the three
months ended March 31, 2002, representing repayments under the line of credit
and capital lease obligations. For the same period ended March 31, 2001, net
cash flow used in financing activities was $59,033, representing advances drawn
on the line of credit of $29,013 offset by repayments on the line and the
capital lease obligations of $88,046.

         Approximately 12% of our total sales in 2001 were attributable to a
single distributor. In the event we were to lose that account, we anticipate
that we would be able to convert the business to dealing directly with the
customers of that distributor. As converted sales would be at a higher margin,
we do not believe the loss of the account would have a material negative impact
on sales.

         The Company's Contractual Obligations and Commercial Commitments are
detailed below:

<TABLE>
<CAPTION>
                                           Payments Due by Period
                        --------------------------------------------------------------
                                        Less
    Contractual                        Than 1        1 - 3        4 - 5      After 5
    Obligations            Total        Year         Years        Years       Years
----------------------  -----------  -----------  -----------  -----------  ----------
<S>                     <C>          <C>          <C>          <C>          <C>
Line of Credit (1)      $  470,064   $  470,064
----------------------  -----------  -----------  -----------  -----------  ----------
Capital Lease
Obligations             $   85,829   $   55,214   $   30,615
----------------------  -----------  -----------  -----------  -----------  ----------
Operating Leases        $  578,031   $  349,164   $  225,597   $    3,270
----------------------  -----------  -----------  -----------  -----------  ----------
Total Cash
Contractual
Obligations             $1,133,924   $  874,442   $  256,212   $    3,270
----------------------  -----------  -----------  -----------  -----------  ----------
</TABLE>


   (1)   This represents the Company's borrowings under its line of credit with
         City National Bank. The City National Bank line of credit provides for

                                       7
<PAGE>

         maximum financing of $1,200,000, bearing interest at prime plus two
         percent, computed on a monthly basis. As of March 31, 2002, the
         interest rate on the line of credit was 6.75% per annum. The Company
         has been making monthly interest payments on the balance. Because the
         line of credit is secured by substantially all of the assets of the
         Company, if the Company were to fall into default under the terms of
         its agreement with City National Bank it could have material adverse
         impact on the Company's business and financial position. The Company
         would be considered to be in default based on the following financial
         conditions:

              o Failure to maintain a tangible net worth plus subordinated debt
                of not less than $1,100,000 at all times.
              o Failure to maintain a ratio of total liabilities to tangible net
                worth plus subordinated debt of not more than 3 to 1 at all
                times.
              o Failure to maintain after-tax profitability of not less than
                $400,000 each year.

         The Company satisfied all of the debt requirements in 2001 except the
requirement of after tax profitability of not less than $400,000. City National
Bank has granted a waiver on the default and has indicated that it will not be
calling the loan. Under the line of credit, we are required to make a pledge of
Key Man Life Insurance on our Chief Executive Officer of up to $750,000. The
officers of the Company have personally guaranteed the line of credit.

         The Company's future funding requirements will depend on numerous
factors, some of which are beyond the Company's control. These factors include
the Company's ability to operate profitably, its ability to recruit and train
management and personnel, and its ability to compete with other, better
capitalized and more established competitors who offer alternative or similar
products to those of the Company. Management believes that, given its positive
working capital position, the Company can satisfy its cash requirements over the
next twelve months from operations if it continues to operate at a profit. The
Company's capital resources and liquidity are expected to be provided by the
Company's cash flow from operations, and in addition, the Company has available
net operating loss carryforwards of approximately $3,000,000 to offset future
taxable income, and continued repayment of notes are expected to act as
contributing factors to the Company's profitability.

         PLAN OF OPERATION

         We intend to expand the Company's position in the vitamin and
nutritional supplements markets. Specifically, our strategy continues to be: (i)
develop new brands and product line extensions, as well as new products, through
our commitment to research and development; (ii) continue the growth of our
balanced distribution network; (iii) build our execution skills through new
operations processes and decision support systems; (iv) achieve cost superiority
through formal productivity benchmarking and continuous improvement programs;
and (v) implement a comprehensive e-commerce plan. The Company believes that its
history and reputation in the field, multiple distribution channels, broad
portfolio of products and packaging and distribution capabilities position it to
be a long-term competitor in the vitamin and nutritional supplements industries.

         During the next twelve months, the Company will continue to work with
Dr. Hoang on his proprietary herbal formulas with a view to developing
additional research that can be marketed to the pharmaceutical and nutraceutical
industries. This process is limited to literature work, including patent
submissions for potential products. The research can be marketed to
pharmaceutical companies either through direct sell of the research to the
pharmaceutical company, or through a joint venture arrangement between the
pharmaceutical company and the Company whereby the parties will jointly own the
patent and continue development of the products. It is our hope that, during the
process of research into possible pharmaceutical and nutraceutical products, we
will test new herbal products, or additional uses for existing herbal products,
that can be added to our current line of products as health food or dietary
supplements.

         In addition to our work in the pharmaceutical and nutraceutical fields
of research, we continue to add new products to our existing product line.
During first quarter 2002, the Company added five new products to its existing
product line. Coag Cal Oxygenation Formula (an herbal formula to support general
circulation), L-Citrulline (an amino acid for optimizing blood flow),

                                       8
<PAGE>

Nattokinase (supports the body in dissolving the unhealthy coagulation of
blood), NeoDerma (provides hydration of the skin and other organs at the
cellular level) and Metabolic Co-Factor (support for utilization and metabolism
of essential fatty acids.)

         Management believes that the Company has good relations with all of its
current manufacturers and suppliers. During 2001, we experienced a concentration
of approximately 56% of our manufacturing with four separate vendors. The
Company does not currently have written contracts with any of its manufacturers,
but relies on long-term personal and professional relationships with its four
largest vendors - Horizon Laboratories at 30%, M&L Pharmaceuticals at 10%, and
Softgel Technologies and ABCO Laboratories, Inc. at 8% each. However, we believe
that, due to the large number of businesses performing this type of service in
the industry, the Company would have little difficulty in finding viable
alternatives in the event any one of these vendors became unable or determined
not to continue manufacturing the Company's products.


CRITICAL ACCOUNTING POLICIES

         Currently, our only real "critical" accounting policy that would be
affected by management judgments and/or uncertainties is the income tax policy.
We have a deferred tax asset on our balance sheet that is recognized primarily
as a result of net operating loss carryforwards. In the event we did not
generate any taxable income within the next year, the asset would be overstated.
Reducing the asset to zero would result in an additional expense in the period
in which it is determined that the asset cannot be realized. This asset
represents approximately 8.2% of our total assets at March 31, 2002

                                       9
<PAGE>

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

         In 1993, a lawsuit was filed in the Circuit Court of the 15th Judicial
Circuit in and for Palm Beach County, Florida by NutriSupplies, Inc., successor
in the interest to rights of Robert H. Harris and the Earth Harvest, Inc.
against NutriCology, Inc. (which has since become a wholly-owned subsidiary of
the Company), Stephen A. Levine (officer, director and beneficial shareholder of
the Company) and Nicholas Gonzales, M.D. This matter is a contract dispute
between Dr. Gonzales and NutriSupplies, Inc., which alleges that Dr. Gonzales
violated their contract agreement and then returned to NutriCology to supply his
patients' needs. NutriCology and Dr. Levine were named in the suit only because
NutriCology had been Dr. Gonzales' supplier. Dr. Gonzales has agreed to fully
indemnify NutriCology and Dr. Levine from any wrongdoing. A motion for summary
judgment was granted in favor of NutriCology, but was appealed. On June 6, 2001,
the appellate court affirmed the grant of that motion, and NutriSupplies has now
filed a Motion for Rehearing and Request for Oral Argument. That motion was
denied and no further appeals have been filed. NutriCology had requested
reimbursement of attorneys' fees, which were denied. NutriCology appealed that
decision, and won. A hearing has been set for June 14, 2002 to determine the
amount of the fees the Company can recover.

ITEM 2.  CHANGES IN SECURITIES AND USE OF PROCEEDS

         None.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

         Not Applicable.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         No matters were submitted to a vote of the Company's shareholders
during the three months ended March 31, 2002.

Item 5.  OTHER INFORMATION

         Not Applicable.

Item 6.  EXHIBITS AND REPORTS ON FORM 8-K

    (a)  Exhibits

         None.

    (b)  Reports on Form 8-K

         None.

                                       10
<PAGE>

                          ALLERGY RESEARCH GROUP, INC.

                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                                  ALLERGY RESEARCH GROUP, INC.
                                                  Registrant



Dated:  May 7, 2002

                                                  By: /s/ Stephen A. Levine
                                                      --------------------------
                                                      Chief Executive Officer

                                       11